Dr. Melanie Orthodontics Opens Rancho Santa Fe Location March 2025
The trusted San Diego orthodontist brings her services to North San Diego County, offering services to more individuals and families and expanding its expert team.
RANCHO SANTA FE, Calif., March 13, 2025 /PRNewswire-PRWeb/ -- Dr. Melanie Orthodontics announces the opening of its new Rancho Santa Fe office on March 3, serving the North San Diego County communities. The location at 16236 San Dieguito Road #4-12 is the second practice for Dr. Melanie Wang, DDS, a trusted family orthodontist transforming smiles with the latest high-tech procedures, such as 3D printing. Special promotions for the grand opening include 25% off retainers and free whitening after any treatment.
Dr. Wang has a unique perspective as a parent to three kids, a caregiver to a child with autism and a board-certified orthodontist. Board certification is voluntary, with only 33% of orthodontists being certified.
Dr. Darshan Dabir, a diplomat of the American Board of Pediatric Dentistry and a senior staff member at Rady Children's Hospital, is joining the team at the new office. He has been in private practice in San Diego County since 2003, providing his patients with the latest treatment options, such as laser dentistry. As a pediatric dentist for over fifteen years, Dr. Dabir has extensive experience providing dental care to infants, children and teens.
"I'm excited to welcome Dr. Dabir to our team and am thrilled he will help me launch a successful practice that is in tune with what families are looking for in dentistry," said Dr. Wang. As a mom, I understand the challenges many may face when searching for an orthodontist who provides kindness and care in a safe, modern office. I've been in your shoes, and I'm here to provide the care and understanding you're looking for. I welcome San Diegans to check out the new location. Dr. Dabir and I look forward to meeting each patient that walks through our door."
Along with Dr. Dabir, Dr. Wang leads the charge in revolutionizing orthodontics with cutting-edge technology and forward-thinking treatments designed to meet the needs of today's patients. She uses 3D AI technology for ultimate accuracy, faster turnaround, increased flexibility, improved comfort and better results. She effectively combines her passion for perfecting smiles with the latest advancements in orthodontic services, ensuring her patients receive the highest quality of care.
For more information, visit http://www.drmelanieorthodontics.com.
About Dr. Melanie Wang: Dr. Melanie Wang is a board-certified orthodontist at Dr. Melanie Orthodontics. With two practices in San Diego County, she grew up in Poway, California and is the oldest daughter of a dentist. As a child, Dr. Melanie never had a cavity. The day she had her braces off was the happiest day of her life! She brings that joy to children and adults today through cutting-edge technology that uses hybrid techniques, 3D printing and the latest advancements in orthodontics to ensure happy patients and bright smiles.
Media Contact
Sarah Castro, Dr. Melanie Orthodontics, 5622713437, scastro@teamchicexecs.com, https://www.drmelanieorthodontics.com/
View original content:https://www.prweb.com/releases/dr-melanie-orthodontics-opens-rancho-santa-fe-location-march-2025-302400653.html
SOURCE Dr. Melanie Orthodontics
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
AlidaBio Launches First Service Provider Partnership with Baylor College of Medicine's GARP Core to Offer Multiplexed RNA Modification Sequencing
SAN DIEGO, June 9, 2025 /PRNewswire/ -- Alida Biosciences, a leader in next-generation RNA modification analysis, is proud to announce its first official service provider: the Genomic and RNA Profiling (GARP) Core at Baylor College of Medicine. This new service offering is powered by AlidaBio's EpiPlex™ Platform, the first and only solution that concurrently detects and quantifies multiple RNA modifications alongside gene expression using short-read sequencing. Officially launched in February 2025, the platform combines the EpiPlex RNA Library Prep Kit with the EpiScout™ Analysis Suite, delivering a complete, single-workflow solution to uncover the functional impact of RNA modifications in development, aging, and disease. Researchers interested in accessing this service can contact the core directly at garpcore@ "We're thrilled to see our first service provider come online at a world-class institution like Baylor College of Medicine," said Dr. Gudrun Stengel, CEO of AlidaBio. "GARP's deep expertise in transcriptomic profiling, combined with our pioneering RNA modification technology, ensures that researchers across disciplines can access this breakthrough capability through an experienced and trusted partner." "This technology represents a significant leap forward in RNA biology," said Dr. Daniel Kraushaar, Director of the GARP Core. "With the ability to simultaneously assess gene expression and multiple RNA modifications, researchers can now gain unprecedented insight into post-transcriptional regulation. We're excited to offer this cutting-edge platform to the Baylor research community and beyond." Designed for clinical and translational research, the EpiPlex Kit is optimized for samples with limited RNA input. With sensitivity down to 50 ng of total RNA, the assay can deliver high-resolution results from challenging materials like tissue biopsies or FFPE samples—where RNA tends to be fragmented and of lower quality. . The accompanying EpiScout Analysis Suite is an intuitive, informatics platform that automates analysis and visualization of complex epitranscriptomic data. By integrating multiple RNA modifications with expression data, researchers gain a multidimensional view of transcriptome regulation without the usual bioinformatics bottlenecks. The EpiPlex assay is automatable and streamlined for efficiency, enabling completion of the wet-lab portion of the workflow in a single day. It is available in 8- and 24-sample formats, supporting labs of any size. Early-access partners across academia and industry have validated the platform's accuracy, reproducibility, and potential for collaborative, large-scale studies. AlidaBio continues to expand the EpiPlex platform, with future plans including additional modification targets, higher base resolution, and targeted panels tailored for drug discovery and disease-specific applications. For more information about AlidaBio's products and services, please visit About Alida BiosciencesFounded in 2020, Alida Biosciences is transforming epigenomics with powerful, user-friendly tools for RNA modification analysis. Our technologies enable concurrent detection and quantification of multiple RNA modifications from clinically relevant samples, supporting breakthroughs in research, therapeutics, and diagnostics. AlidaBio is backed by Genoa Ventures, FusionX Ventures, General Inception and Vertical Venture Partners, and supported by SBIR grants from the NHGRI. Media Contact Nikita Warnernwarner@ View original content to download multimedia: SOURCE Alida Biosciences Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Santiam Hospital and Clinics enters into Prime Vendor agreement with Medline
Oregon-based hospital taps into Medline's custom pack capabilities and distribution services NORTHFIELD Ill., June 9, 2025 /PRNewswire/ -- Medline today announced a new multi-year Prime Vendor agreement with Oregon-based not-for-profit hospital Santiam Hospital and Clinics, one of only three independent acute-care hospitals in the state. With its dedication to customer service and relentless focus on supply chain reliability, Medline will provide high-quality distribution services to help Santiam Hospital service its more than 40,000 patients annually across 11 clinics – including satellite clinics – with more than 500 employees, including 60 medical staff. "We are thrilled to finalize the Prime Vendor agreement, marking a new chapter of collaboration," said Ryan Dickson, acute care division director, Medline. "This is a testament to our Medline team and our ability to partner with our customers to help solve their most complex supply chain and standardization problems, delivering when they need us most. We look forward to what the future holds with this exciting new agreement." In addition to improved supply chain resiliency and customer support, Medline will work with Santiam Hospital and its clinics to prioritize standardization of sterile procedure trays (SPTs) to improve patient outcomes and reduce healthcare costs. Medline's state-of-the-art distribution center in Portland, Ore., will service Santiam Hospital, providing the supplies it needs across all 11 locations. Learn how Medline supports hospitals and clinics to improve clinical, financial and operational outcomes at About MedlineMedline is the largest provider of medical-surgical products and supply chain solutions serving all points of care. Through its broad product portfolio, resilient supply chain and leading clinical solutions, Medline helps healthcare providers improve their clinical, financial and operational outcomes. Headquartered in Northfield, Illinois, the company employs more than 43,000 people worldwide and operates in more than 100 countries and territories. To learn more about how Medline makes healthcare run better, visit Natalie Schlueter(847) 721-6822nschlueter@ FacebookTwitterLinkedInYoutube View original content to download multimedia: SOURCE Medline Industries, LP Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Nontuberculous Mycobacterial (NTM) Diagnostic Market to Reach USD 3,261.1 million By 2032, Growing At An 6.64% CAGR
PUNE, India, June 9, 2025 /PRNewswire/ -- According to the latest research by Credence Research, the global Nontuberculous Mycobacterial (NTM) Diagnostic Market was valued at USD 1,814.8 million in 2023 and is projected to reach USD 3,261.1 million by 2032, growing at a compound annual growth rate (CAGR) of 6.64% during the forecast period. The rising incidence of NTM infections, especially among immunocompromised patients and individuals with chronic pulmonary conditions, is a primary factor driving market demand. Technological advancements in molecular diagnostics and imaging techniques are significantly enhancing detection accuracy and speed, leading to faster diagnosis and improved clinical outcomes. Healthcare providers are increasingly adopting advanced diagnostic platforms to address the complexities of identifying NTM species, which often mimic other pulmonary disorders. This shift is further supported by growing awareness of NTM-related diseases and stronger clinical guidelines for early screening and diagnosis. Expanding healthcare infrastructure across emerging markets, coupled with increased investments in R&D by diagnostics companies, is expected to accelerate market expansion over the coming years. Browse the report and understand how it can benefit your business strategy- Key Growth Determinants: Nontuberculous Mycobacterial (NTM) Diagnostic Market The growth of the NTM Diagnostic Market is primarily driven by the rising global prevalence of NTM infections, particularly among the aging population and individuals with underlying lung conditions such as COPD, bronchiectasis, and cystic fibrosis. As awareness of these infections increases among healthcare professionals, the demand for timely and accurate diagnostic solutions is expanding. This trend is supported by an uptick in hospital admissions and outpatient consultations related to unexplained pulmonary symptoms, where NTM is an emerging differential diagnosis. Another key growth determinant is the rapid advancement in diagnostic technologies. Innovations in molecular diagnostics, PCR-based assays, and next-generation sequencing (NGS) are enabling faster, more precise identification of various NTM species, overcoming the limitations of traditional culture methods. Furthermore, increased funding for infectious disease research and growing collaborations between public health organizations and diagnostic manufacturers are creating favorable conditions for product development and market penetration. The rising implementation of clinical guidelines recommending early testing for at-risk populations is also bolstering the adoption of advanced NTM diagnostics globally. Key Growth Barriers: Nontuberculous Mycobacterial (NTM) Diagnostic Market Limited Awareness and MisdiagnosisMany clinicians and patients remain unaware of NTM infections, which often mimic tuberculosis or other chronic pulmonary conditions. This lack of awareness leads to frequent misdiagnosis or delayed testing, particularly in settings with limited diagnostic infrastructure. Diagnostic Complexity and InaccessibilityAccurate identification of NTM species is essential for effective treatment, but traditional culture methods are time-consuming and may lack sensitivity. Advanced molecular diagnostic tools, though more effective, are not widely accessible in many regions, especially in developing markets. Resource Constraints in Healthcare FacilitiesComprehensive NTM diagnostics require specialized laboratory equipment, trained personnel, and standardized testing protocols. Many healthcare systems, especially in low- and middle-income countries, face limitations in implementing such advanced diagnostics. Regulatory and Reimbursement ChallengesNavigating regulatory approval for new diagnostic tools can be time-consuming and costly. In addition, limited reimbursement policies for advanced NTM diagnostic tests discourage healthcare providers from adopting innovative solutions. Segmentation Based on Diagnostic Method: Nucleic Acid Amplification Tests (NAAT) Microscopy Culture-based Methods Biochemical Tests Immunological Tests PCR Others Based on Infection Type: Pulmonary Cutaneous Disseminated Gastrointestinal Others Based on End-User: Hospitals & Clinics Diagnostic Laboratories Others Based on region North America Europe Asia Pacific Latin America Middle East & Africa Preview the report with a detailed sample and understand how it can benefit your business strategy. Request a free sample today - Regional Analysis: Nontuberculous Mycobacterial (NTM) Diagnostic Market North America holds the largest share of the global NTM Diagnostic Market, accounting for approximately 39% of total revenue in 2023. This dominance is driven by advanced healthcare infrastructure, widespread use of molecular diagnostic technologies, and high awareness of NTM-related diseases. The presence of major diagnostic companies and strong R&D funding further support market growth in the United States and Canada. Europe follows with around 27% of the market share. Countries like Germany, the UK, and France are key contributors, supported by growing recognition of NTM infections, aging populations, and well-established public health systems. Increased focus on early diagnosis and the adoption of advanced testing tools continue to fuel regional demand. Asia-Pacific accounts for roughly 23% of the global market. Rapid improvements in healthcare infrastructure, growing patient awareness, and increased investments in diagnostic technologies are propelling growth in China, Japan, South Korea, and India. Partnerships between international diagnostic firms and regional players are expanding access to accurate NTM testing. Latin America represents about 6% of the market, led by Brazil, Mexico, and Argentina. Market growth is supported by public health campaigns and improved diagnostic capabilities, though infrastructure disparities in remote areas remain a challenge. Middle East & Africa comprise the smallest share, approximately 5% in 2023. While diagnostic capacity remains limited in many parts of the region, targeted investments in laboratory services and healthcare modernization—especially in the GCC and South Africa—are gradually improving market potential. Credence Research's Competitive Landscape Analysis Credence Research's Competitive Landscape Analysis presents a clear and focused view of key industry players in the NTM diagnostic segment with a spotlight on strategic strengths and market positioning: Credence Research identifies a handful of dominant multinational diagnostics firms—Thermo Fisher Scientific Inc., F. Hoffmann‑La Roche Ltd, Becton, Dickinson & Company (BD), and bioMérieux SA—as frontrunners in the global NTM diagnostic market. These companies differentiate themselves via wide-ranging product portfolios that encompass both molecular and immunological diagnostic tools. They cater to centralized laboratory settings and decentralized testing environments, ensuring flexibility across different healthcare infrastructures. Their strong investment in R&D, global distribution networks, and robust service support contribute to their sustained competitive edge and rapid product adoption. Through its analysis, Credence Research highlights how these industry leaders are not only maintaining market dominance but also expanding access to advanced NTM diagnostic solutions via collaborations, innovative product development, and targeted regional strategies—positioning themselves to capitalise on the projected market growth. Tailor the report to align with your specific business needs and gain targeted insights. Request Full Report Here- Key Player Analysis Thermo Fisher Scientific Inc Hoffmann-La Roche Ltd Becton, Dickinson and Company (BD) bioMérieux SA Bruker Corporation SD Biosensor Bioneer Seegene Inc. Recent Industry Developments June 2025 – Thermo Fisher Scientific introduced two advanced mass spectrometry instruments—the Orbitrap Astral Zoom and Orbitrap Excedion Pro—during the ASMS conference. Designed primarily for proteomics and biopharma applications, these systems deliver enhanced speed and sensitivity, significantly advancing the analysis of complex biological samples. Their improved resolution and throughput have potential applications in infectious disease diagnostics, including NTM-related testing. December 2024 – Shanghai MicuRx Pharmaceutical ( announced that the U.S. FDA granted Orphan Drug Designation (ODD) to its investigational anti-infective drug MRX-5 for the treatment of NTM infections, representing a significant step in developing targeted therapies for this condition. September 2023 – QIAGEN entered a strategic partnership with a major South Asian healthcare provider to integrate its proprietary diagnostics into regional laboratories, enhancing capabilities for detecting and managing NTM infections. August 2023 – bioMérieux expanded its infectious disease portfolio through the acquisition of a biotech company specializing in NTM diagnostics. July 2023 – Hologic, Inc. secured regulatory approval for a new diagnostic test specifically developed to identify NTM infections, reinforcing its commitment to infectious disease diagnostics. January 2022 – Gaelan Medical Trade LLC partnered with RedHill Biopharma Ltd. to distribute Talicia (omeprazole magnesium, amoxicillin, and rifabutin) in the United Arab Emirates. Though primarily approved for H. pylori, its components hold relevance in mycobacterial infection strategies. February 2021 – Koninklijke Philips N.V. completed the acquisition of BioTelemetry, Inc., a leader in remote monitoring and diagnostics, potentially expanding future integration of infectious disease tracking technologies. Reasons to Purchase this Report: Gain a comprehensive understanding of the market through qualitative and quantitative analyses, considering both economic and non-economic factors, with segmentation and sub-segmentation details provided in terms of market value (USD Billion). Identify regions and segments expected to experience the fastest growth or dominate the market, with a detailed analysis of geographic consumption patterns and the factors driving or hindering market performance in each region. Stay informed about the competitive environment, with rankings of major players, recent product and service launches, partnerships, business expansions, and acquisitions from the past five years. Access detailed profiles of major market players, including company overviews, insights, product benchmarking, and SWOT analysis, to understand competitive advantages and market positioning. Explore the present and forecasted market landscape, with insights into growth opportunities, market drivers, challenges, and constraints for both developed and emerging regions. Benefit from Porter's Five Forces analysis and Value Chain insights to evaluate various market perspectives and competitive dynamics. Understand the evolving market scenario, including potential growth opportunities and trends expected in the coming years. Browse the report and understand how it can benefit your business strategy - Discover additional reports tailored to your industry needs Ocular Drug Delivery System Market - Pharma Grade Synthetic Camphor Market - Topical Drug Delivery Market - Lidocaine Market - Dermatology and Eye Care Services Market - Metabolism Assays Market - Dental Implantology Drill Bit Market - Dental Implantology Drill Bit Market - Tetrabenazine Market - Follow Us: About Us: Credence Research is a viable intelligence and market research platform that provides quantitative B2B research to more than 2000 clients worldwide and is built on the Give principle. The company is a market research and consulting firm serving governments, non-legislative associations, non-profit organizations, and various organizations worldwide. We help our clients improve their execution in a lasting way and understand their most imperative objectives. Contact Us Mitul DeanTower C-1105 , S 25, Akash Tower,Vishal Nahar, Pimple Nilakh, Haveli,Pune – 411027, Indiasales@ Logo - View original content to download multimedia: SOURCE Credence Research Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
